ABBV · News · 20260805N
Revenue Performance and Mix
AbbVie Inc. · 2026-08-05 · Importance 54 · Surprise 40 · No source text
AbbVie reported second-quarter 2026 revenue of $16.99 billion, up 10.2% year over year and above analyst expectations. Skyrizi and Rinvoq delivered strong growth and helped offset declining Humira revenue. Adjusted EPS was $3.65, exceeding analyst forecasts alongside the revenue beat.
Key facts
- AbbVie reported revenue up 10.2% year-over-year in Q2 2026. source
- AbbVie reported Q2 2026 revenue of $16.99 billion and adjusted EPS of $3.65. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +10.2% | AbbVie reported revenue up 10.2% year-over-year in Q2 2026. |